反应详情

A solution of tert-butyl 4-(6-(4-aminophenyl)-4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate (130 mg, 0.26 mmol) in dichloromethane (5 mL) was treated with triphosgene (37 mg, 0.12 mmol) as a solution in dichloromethane (2 mL). After the passage of five minutes, the appropriate nucleophile—in this case, 2.0 M methylamine solution in tetrahydrofuran (2 mL)—was added to the resulting isocyanate mixture. After 30 minutes of stirring at room temperature, the mixture was concentrated to dryness under reduced pressure. The residue was purified via reverse-phase high performance liquid chromatography using a Phenomenex Prodigy 21 mm×250 mm column, running a gradient elution of 5% acetonitrile/95% of 0.1% aqueous trifluoroacetic acid to 100% acetonitrile. After the concentration of fractions under reduced pressure, tert-butyl 4-[6-{4-[(methylcarbamoyl)amino]phenyl}-4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate was obtained. MS (ES+): 563.4 (M+H)+

1. concentrationthe mixture was concentrated to dryness under reduced pressure
2. customThe residue was purified via reverse-phase high performance liquid chromatography
3. washa gradient elution of 5% acetonitrile/95% of 0.1% aqueous trifluoroacetic acid to 100% acetonitrile